MedTrace Logo

Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients

NCT01385696 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2015-06-24

Study results available
· View outcomes & findings →

Summary

Preference study: Genuair vs HandiHaler inhalers in COPD patients.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DEVICE

Genuair® (Almirall S.A.)

Inhaler with only placebo, once daily, 14 days

DEVICE

HandiHaler® (Boehringer Ingelheim's)

Inhaler with only placebo, once daily, 14 days

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Jordi Estruch, Head of GMA · Almirall, S.A.

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01385696 on ClinicalTrials.gov